In Vitro Toxicology Testing Services: Timely, Effective Toxicity Analysis

Rapidly assess therapeutic candidates’ potential for drug-drug interactions and accurately predict xenobiotic-induced liver toxicity with INDIGO’s in vitro
toxicology testing Services.

Multichannel pipette dispensing liquid into a 96 well plate

Get Reliable Data & Clear Toxicity Reports from Our Expert Scientists


Affordable In Vitro Toxicology Solutions

Reliable and cost-effective, we offer in vitro toxicity testing services designed to provide the answers you need.


Fast Screening & Data Delivery

Access crucial toxicology information quickly with INDIGO’s in vitro toxicity testing services.


Detailed Reports & Available Technical Support

Our team delivers high-quality data analysis and reviews, putting INDIGO’s many years of experience at your service.

Hepatotoxicity Assay using Highly Stable & Functional upcyte® Hepatocytes

INDIGO’s in vitro screening services for drug-induced hepatotoxicity allow for early assessment of drug candidates, lowering risks of clinical trial termination and post-market withdrawal.

Using single-donor upcyte® Hepatocytes, INDIGO’s hepatotoxicity assays enable accurate, large-scale testing even over extended periods.

Engineered with the ability to proliferate while maintaining key features of primary cells, upcyte® Hepatocytes are highly stable, offering unparalleled assay reproducibility.


Human P-Glycoprotein/MDR1 Drug Interaction Assay Services

Get your therapeutic candidates screened early and quickly identify their potential effects on P-gp, also known as MDR1, a key protein involved in cross-membrane drug transport.

Upgrade your safety assessment process with INDIGO’s Human P-Glycoprotein (P-gp) Interaction Assay Services and fast-track your drugs to FDA validation.

Applications for INDIGO’s In Vitro Toxicity Testing Assays


Rapidly evaluate the safety profile of drug candidates and rule out those showing potential liver toxicity with INDIGO’s Hepatotoxicity Assay Services.


Effectively detect liver toxicity from chemical contaminants of emerging concern in the environment using INDIGO’s in vitro toxicology testing services.

Get Started in Three Simple Steps

Design your next study rapidly and confidently with our expert team.


Step 1: Request a Quote in One Click

Fill out a Request a Quote form and tell us more about your study and objectives.


Step 2: Design Your Service Study with Our Scientists

Receive your quote and a custom draft of your Service Work Order.

Review and adjust to fit your needs.


Step 3: Send Your Samples and Get Your Results

Provide your samples or compounds, and we will do the rest.

Receive a complete data package and clear study reports in record time!

Transform your vision into clear results today.

See What Our Customers Have to Say

“I think if we had gone with anyone else, we would still be running assays rather than having confidence in the data that we've gained with INDIGO.”


Principal Scientist

“I really appreciate their detailed reports.”



“The experiment turn-over time was fast, yet data package and report were of great quality.”


Associate Director

Frequently Asked Questions

INDIGO’s assays are not binding assays. They are cell-based trans-activation assays, and the principal application is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that the compounds may exert against the nuclear receptors. INDIGO reporter systems utilize firefly luciferase reporter gene technology, and while there is a binding taking place, our assays do not measure it. Instead, the luciferase light response is measured which correlates to the activation status of the receptor (either activation or inhibition).

Quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in receptor activity. It will tell the scientist the significance (strength) of the interaction by the level of light emitted. In addition, cell-based assays are more sensitive and able to detect smaller levels of activation.

INDIGO’s nuclear receptor assays utilize proprietary human and non-human mammalian cells engineered to provide constitutive, high-level expression of the designated receptor. Specific cell type information for each assay is proprietary and available only through consultation with INDIGO’s technical team following a screening service or assay kit purchase.

Reporter cells included in INIDIGO’s steroid hormone nuclear assay kits (ERα, ERβ, AR, PGR, MR, GR) express the native, full-length receptors. INDIGO’s other nuclear receptor assays, however, include reporter cells that express hybrid nuclear receptors. In these cases, the respective receptor’s native N-terminal sequence comprising the DNA Binding Domain (DBD) has been replaced with sequence encoding the yeast Gal4-DBD. All other native NR functional/structural domains (ligand binding domain, hinge region, and various activation domains) are present in these hybrid receptors.

These reporter cells also contain the firefly luciferase reporter gene functionally linked to the upstream genetic response element for Gal4. Consequently, once a bioactive compound associates with the ligand binding domain of the hybrid receptor, only the luciferase reporter gene is induced. Ligand-activation of the hybrid receptor will not induce collateral expression of target genes that are otherwise regulated by the native nuclear receptor.

View our list of reference compounds. We do utilize commercially available reference agonists for our assays, and this reference agonist is included in each assay kit. We do use reference antagonists where a reference is known and commercially available. Some of our antagonist assays do not have reference antagonists available.

Treatment concentrations are prepared at INDIGO using serial dilutions in fixed increments; the starting concentration and increment of dilution is specified by the customer via our Study Work Order sheet that accompanies all screening studies. For accurate determination of EC50 and/or IC50 values, we recommend at minimum spanning a 5,000-fold concentration range over 8 doses. This strategy requires a 3.33-fold or 4-fold increment of serial dilution. The minimum doses recommended for EC50 and/or IC50 value is 7 test concentrations.

Upon completion of your study, you will receive a detailed study report (PDF format) including all assay methods and validation, the raw data and calculations of your study (Excel format), and graphing files of all data (GraphPad Prism format). In addition, you are always welcome to contact INDIGO’s team for assistance in interpretation of your data.

Related Services

Automatic pipette dispensing into a 96 well plate

Reporter Assay Services

Explore our screening services and choose your next assay from our extensive portfolio of cell-based receptor assays

Residual sample within a 96 well reaction plate

Expression Profiling

Opt for our expression profiling services and gain insights into disease-, metabolism- and pathway-specific-related gene expression fast.

Loading test samples into a multiwell reaction plate

Custom Assay Development

Let us develop a customized, high-performing assay tailored to your needs.